SEC Filing Summary: Spherix Incorporated (Form 10-Q)
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2008. Spherix Incorporated operates two principal segments following the August 2007 sale of its InfoSpherix subsidiary: BioSpherix, focused on the development and commercialization of "Naturlose" (tagatose) for Type 2 diabetes treatment, and Health Sciences, a consulting business launched in July 2007. The company is currently conducting a Phase 3 clinical trial for Naturlose.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2008 | Nine Months Ended Sep 30, 2008 |
|---|---|---|
| Revenue | $307,714 | $713,773 |
| Net Loss (Continuing Ops) | $(1,735,442) | $(4,847,949) |
| Operating Expenses | $2,103,553 | $5,847,331 |
| Cash and Cash Equivalents | $7,474,408 | $7,474,408 (Balance Sheet) |
| Short-term Investments | $2,944,664 | $2,944,664 (Balance Sheet) |
| Total Current Assets | $11,053,532 | $11,053,532 (Balance Sheet) |
| Total Liabilities | $1,748,165 | $1,748,165 (Balance Sheet) |
| Working Capital | $10,043,714 | $10,043,714 (Calculated) |
Note: The filing text does not provide a specific "cash flow from operations" line item for the three-month period, but reports net cash used in operating activities for the nine months ended September 30, 2008, as $(5,221,569).
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased significantly from $58,500 in the prior year quarter to $307,714, driven by the Health Sciences consulting segment. BioSpherix generated negligible revenue ($5,000 for the nine months).
- Reduced Loss: The net loss from continuing operations narrowed to $(1.74M) for the quarter compared to a loss of $(3.10M) in the prior year quarter (excluding discontinued operations). The prior year included a significant income tax benefit related to the sale of InfoSpherix.
- Expense Reduction: General and administrative expenses decreased due to the relocation of headquarters to a smaller facility in April 2008.
- Cash Position: Cash and cash equivalents decreased from $15.8M at year-end 2007 to $7.5M at September 30, 2008, primarily due to R&D expenditures for the Phase 3 clinical trial and investments in short-term securities.
Outlook, Risks, and Management Commentary
- Clinical Trial Status: Patient recruitment for the Phase 3 Naturlose trial has been slower than expected. The company is expanding trials to India and modifying delivery methods to improve enrollment. Completion is now expected in 2010.
- Liquidity and Capital Needs: Management expects to expend approximately $6 million over the next year. While current resources may suffice to complete the Phase 3 trial, additional capital will likely be required for FDA application and commercialization. The company is considering raising funds via stock sales.
- Nasdaq Compliance Risks: The company received notice of non-compliance with Nasdaq's $1.00 minimum bid price requirement. A special meeting is scheduled for November 17, 2008, to vote on a reverse stock split. Additionally, the company transferred its listing from the Nasdaq Global Market to the Nasdaq Capital Market due to stockholders' equity falling below the $10 million threshold.
- Escrow Proceeds: The company expects to receive $2 million in escrow proceeds from the InfoSpherix sale in November 2008.
Investor Verification Checklist
- Verify the timeline and enrollment rates of the Phase 3 clinical trial for Naturlose, as delays could deplete cash reserves.
- Confirm the outcome of the November 17, 2008, special meeting regarding the proposed reverse stock split to avoid delisting.
- Monitor the company's ability to raise additional capital in the current economic climate to fund post-trial commercialization.
- Track the receipt of the $2 million escrow payment from the InfoSpherix sale in November 2008.
- Assess the revenue sustainability of the Health Sciences consulting segment as the primary cash generator.